María Barca-Hernando , Alberto García-Ortega , Amaya Martínez-Meñaca , M. Purificación Ramírez-Martín , Agustina Rivas-Guerrero , Andrés Tenes
{"title":"肺血栓栓塞症","authors":"María Barca-Hernando , Alberto García-Ortega , Amaya Martínez-Meñaca , M. Purificación Ramírez-Martín , Agustina Rivas-Guerrero , Andrés Tenes","doi":"10.1016/j.opresp.2024.100342","DOIUrl":null,"url":null,"abstract":"<div><p>Pulmonary embolism (PE), the most severe form of presentation of venous thromboembolic disease (VTE), currently represents a foremost healthcare issue due to its high impact in terms of morbidity, mortality, costs, and resource consumption. Early mortality associated with PE is primarily due to hemodynamic instability, exacerbation of pre-existing conditions, or major complications of antithrombotic therapies. Beyond the risk of death, there are relevant complications related to PE, such as bleedings, VTE recurrences, and persistence of residual respiratory symptoms; the latter complication related to PE is mainly characterized by two entities, chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease. Significant scientific advances made in recent years have allowed for the improvement of both diagnostic and therapeutic management of the disease, as outlined in this document through a series of relevant issues about PE that are answered with the most up-to-date scientific evidence.</p></div>","PeriodicalId":34317,"journal":{"name":"Open Respiratory Archives","volume":"6 4","pages":"Article 100342"},"PeriodicalIF":0.0000,"publicationDate":"2024-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2659663624000456/pdfft?md5=bd59add918a6676b63b6441f2a816443&pid=1-s2.0-S2659663624000456-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Tromboembolia de pulmón\",\"authors\":\"María Barca-Hernando , Alberto García-Ortega , Amaya Martínez-Meñaca , M. Purificación Ramírez-Martín , Agustina Rivas-Guerrero , Andrés Tenes\",\"doi\":\"10.1016/j.opresp.2024.100342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Pulmonary embolism (PE), the most severe form of presentation of venous thromboembolic disease (VTE), currently represents a foremost healthcare issue due to its high impact in terms of morbidity, mortality, costs, and resource consumption. Early mortality associated with PE is primarily due to hemodynamic instability, exacerbation of pre-existing conditions, or major complications of antithrombotic therapies. Beyond the risk of death, there are relevant complications related to PE, such as bleedings, VTE recurrences, and persistence of residual respiratory symptoms; the latter complication related to PE is mainly characterized by two entities, chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease. Significant scientific advances made in recent years have allowed for the improvement of both diagnostic and therapeutic management of the disease, as outlined in this document through a series of relevant issues about PE that are answered with the most up-to-date scientific evidence.</p></div>\",\"PeriodicalId\":34317,\"journal\":{\"name\":\"Open Respiratory Archives\",\"volume\":\"6 4\",\"pages\":\"Article 100342\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-06-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2659663624000456/pdfft?md5=bd59add918a6676b63b6441f2a816443&pid=1-s2.0-S2659663624000456-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Open Respiratory Archives\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2659663624000456\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Open Respiratory Archives","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2659663624000456","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
摘要
肺栓塞(PE)是静脉血栓栓塞性疾病(VTE)最严重的表现形式,由于其在发病率、死亡率、成本和资源消耗方面的巨大影响,目前已成为医疗保健领域的首要问题。与 PE 相关的早期死亡率主要是由于血流动力学不稳定、原有疾病加重或抗血栓治疗的主要并发症。除死亡风险外,还有一些与 PE 相关的并发症,如出血、VTE 复发和残留呼吸道症状持续存在;与 PE 相关的后一种并发症主要有两种情况,即慢性血栓栓塞性肺动脉高压和慢性血栓栓塞性疾病。近年来取得的重大科学进步改善了对该疾病的诊断和治疗管理,本文件通过一系列与 PE 相关的问题,以最新的科学证据对这些问题进行了概述。
Pulmonary embolism (PE), the most severe form of presentation of venous thromboembolic disease (VTE), currently represents a foremost healthcare issue due to its high impact in terms of morbidity, mortality, costs, and resource consumption. Early mortality associated with PE is primarily due to hemodynamic instability, exacerbation of pre-existing conditions, or major complications of antithrombotic therapies. Beyond the risk of death, there are relevant complications related to PE, such as bleedings, VTE recurrences, and persistence of residual respiratory symptoms; the latter complication related to PE is mainly characterized by two entities, chronic thromboembolic pulmonary hypertension and chronic thromboembolic disease. Significant scientific advances made in recent years have allowed for the improvement of both diagnostic and therapeutic management of the disease, as outlined in this document through a series of relevant issues about PE that are answered with the most up-to-date scientific evidence.